Auditing matters
Dutch gene therapy play uniQure has nominated Jack Kaye to its Board of Directors. Kaye will also chair the uniQures Audit Committee.
Kaye, who holds a Bachelor of Business Administration from Baruch College in New York and is a Certified Public Accountant, is currently chairman of the Audit Committee and a member of the Compensation Committee of Dyadic International. Previously, he served as chairman of the Audit Committee of Keryx Biopharmaceuticals. From 1978 till 2006, he was a partner of international accounting, tax and consulting firm Deloitte.
uniQure is intending to transition from the current two-tier Supervisory Board and Management Board structure to a single Board of Directors with executive and non-executive members.
Biocytogen Co Ltd
Draupnir Bio ApS